1138 GMT - European defense and pharmaceutical stocks are expected to perform strongly beyond 2025, Moody's analysts Martin Kohlhase and Marina Albo say in a note to investors. Europe's defense companies continue to benefit from structural demand drivers that are unlikely to abate in the next years, they say. Their order books are strong and cover between two and five years of revenue, they write. Global supply-chain challenges affecting aerospace and defense companies pose the main risk to Moody's double-digit percentage operating profit growth forecast for 2025, they note. Meanwhile, demand for weight-loss and diabetes drugs as well as the strong growth of oncology and immunology treatments should keep pharmaceutical stocks high, the analysts say. (cristina.gallardo@wsj.com)
(END) Dow Jones Newswires
November 20, 2024 06:40 ET (11:40 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.